Fentanyl is a rapid-acting, short duration opioid analgesic agent. In recent years, increased prescription and illicit use of fentanyl drugs have led to major safety concerns and a growing death toll. However, the causes of fentanyl-induced fatal adverse effects have not been thoroughly researched. This study investigated P-glycoprotein (P-gp) modulated blood-brain barrier penetration of fentanyl and its resulting toxicity in vitro and in vivo. ATPase assays were performed together with bi-directional transport assays using Caco-2 cells in the presence and absence of tariquidar, a P-gp inhibitor, to confirm the P-gp substrate property of fentanyl. In vivo determinations of brain pharmacokinetic profile, duration of loss of righting reflex, and respiratory function were further conducted following intravenous administration of low and high doses of fentanyl with and without tariquidar in rats. Fentanyl significantly increased the ATPase activity of P-gp membrane. The efflux ratio of fentanyl on Caco-2 cells was >2, which was remarkably reduced when co-incubated with tariquidar. Using concomitant tariquidar with fentanyl (40 lg/kg) in rats, the unbound brain-to-plasma concentration ratio in rats increased 2.9-fold. The duration of loss of righting reflex was significantly extended, and fentanyl-induced respiratory depression was aggravated. At high fentanyl doses (80 mg/kg), inhibition of P-gp resulted in severe respiratory toxicity in the rats and even death. Collectively, these results gave strong evidence that P-gp plays a vital role in fentanyl blood-brain barrier penetration and the resulting toxicity. Fentanyl requires close monitoring in clinic when administered concomitantly with P-gp inhibitors.
Millions of people worldwide suffer from poorly treated pain. Opioid analgesics are among the most effective agents currently available for treating pain. Fentanyl is a synthetic l-opioid receptor agonist with a potent analgesic effect. Because of its minimal cardiovascular side effects and rapid onset and withdraw of action, it is the most commonly used medication to treat acute and perioperative pain as well as chronic pain in cancer patients (Twycross et al., 2012) . Moreover, transdermal fentanyl has been used in nonmalignant pain relief (Kornick et al., 2003) . As a powerful analgesic, the prescription of fentanyl has increased dramatically in recent years (Latimer et al., 2016) . Meanwhile, fentanyl-associated mortality is a growing threat to public health and safety. In 2014, over 10 million individuals in the United States reported the use of illicit opioids as well as prescription opioids for nonmedical reasons, contributing to drug-related overdose (Suzuki and El-Haddad, 2017) . According to the Centers for Disease Control of Florida, fentanyl-associated mortality in 2015 was 6.5 times higher when compared with 2010 (Ramsey et al., 2017) . U.S. DEA issued a nationwide alert on fentanyl as threat to health and public safety (Drug Enforcement Administration, 2015) . Current documents show that therapeutic misuse, abuse and illicit use of fentanyl are the main factors leading to the outbreaks of fentanyl overdoses and increased death rate (Fodale et al., 2008; LoVecchio and Ramos, 2011; Martin et al., 2006; Suzuki and El-Haddad, 2017) . Multidrug usage was also considered as one of the causes (Serghini et al., 2015) . However, to date the toxicological mechanism of fentanylinduced overdose death has not been thoroughly investigated.
Pharmacologically, fentanyl behaves as a highly effective full agonist at the l-opioid receptor with steep concentrationresponse curves (Yassen et al., 2008) . Due to its relatively narrow therapeutic window, altered systemic or central nervous system (CNS) exposure may lead to severe consequences. Most previous studies have mainly focused on cytochrome P450 (CYP) inhibition-mediated drug interaction, as fentanyl is a CYP3A substrate (Levin et al., 2010) . CYP3A5 variant alleles in patients could affect the plasma exposure and nonrenal clearance of fentanyl (Fodale et al., 2008; Tanaka et al., 2014) . In clinical studies, it has been observed that systemic exposure of fentanyl was increased to 133% by ketoconazole (Ziesenitz et al., 2015) . Both voriconazole and fluconazole delayed the elimination of intravenously dosed fentanyl; however, the initial plasma concentration was not affected (Saari et al., 2008) . Fentanyl dosage adjustments were proposed in patients with genetic deficiency or when coadministered with strong CYP3A inhibitors.
In addition to CYP3A-mediated metabolic elimination, it is well accepted that the penetration of the blood-brain barrier (BBB) is pivotal for fentanyl CNS opioid effects, including analgesia and respiratory depression. Increasing evidence indicates that efflux transporters on BBB, specifically P-glycoprotein (P-gp), may contribute to the development of tolerance toward opioids. P-gp (also known as MDR1 or ABCB1) mediates the ATP-dependent export of drugs from cells. It is expressed in the luminal membrane of the small intestine and BBB, and in the apical membranes of excretory cells such as hepatocytes and kidney proximal tubule epithelia (Giacomini et al., 2010) . It provides a natural mechanism for harmful foreign substances entering into the CNS (Linnet and Ejsing, 2008) . Several studies have suggested that fentanyl is a substrate of P-gp (Hamabe et al., 2006; Tang et al., 2002; Yamazaki et al., 2001 ). An in vivo study showed that the antinociceptive effect of fentanyl in mdr1-knockout (KO) mice was 2-fold higher than in wide-type mice (Hamabe et al., 2006) . In humans, researchers have observed that ABCB1 polymorphisms might have clinical relevance to respiratory suppression induced by intravenously dosed fentanyl (Park et al., 2007) . In contrast, 1 study showed that fentanyl did not behave as a P-gp substrate in Caco-2 cells, but inhibited P-gp-mediated digoxin transport (Wandel et al., 2002) . Moreover, in a human study, coadministration with quinidine increased oral fentanyl systemic absorption, but showed less impact on fentanyl CNS effects, such as miosis (Kharasch et al., 2004) . The authors suggested that P-gp played a role mainly in the intestinal disposition of fentanyl, but not at BBB. Overall, there appear to be some controversies over the involvement of P-gp in fentanyl penetration across the BBB (Gharavi et al., 2015) .
To date, the exact role of P-gp in fentanyl brain access remains unknown. Thus, the objectives of this study were: (1) to assess P-gp substrate property of fentanyl; (2) to examine the role of P-gp at BBB on fentanyl's exposure; and (3) to determine whether P-gp modulated brain exposure was associated with CNS toxicity of fentanyl.
MATERIALS AND METHODS

Chemicals
Fentanyl was purchased from the National Institute of Food and Drug Control (Beijing, China) with the purity >99%. P-gp and breast cancer resistance protein (BCRP) membranes and ATPase assay kit were purchased from BD Genetest Co. (Woburn, Massachusetts). Digoxin and sulfasalazine were purchased from Sigma Chemical Co. (St Louis, Missouri) . Tariquidar (purity > 98%) was purchased from APE BIO company (Huston, USA). HPLC-grade methanol and acetonitrile were purchased from Thermo Fisher Scientific (Waltham, USA). All other chemicals and reagents were of analytical grade.
In Vitro Studies
ATPase assay with P-Gp and BCRP membranes. The ATPase assay was performed using a BD Gentest ATPase assay kit following the instruction manual. The assay mixtures containing P-gp or BCRP membrane were pre-incubated with fentanyl (1 mM) for 5 min. The reactions were started by addition of MgATP, followed by incubation at 37 C for 30 min. The reactions were terminated with a stop solution (10% SDS solution). Colordeveloping reagent was then added and incubated for another 20 min before taking the absorption reading at 800 nm. To validate the membrane transporter activities from commercial sources, digoxin (10 mM) and sulfasalazine (30 mM) were tested as P-gp-and BCRP-positive control substrates. The stimulated ATPase activities, measured as a consequence of substrate binding to the transporters, were calculated by dividing the amount of inorganic phosphate produced during the incubation time and the amount of protein used in the incubation.
Caco-2 cell transport assays. Bi-directional transport of fentanyl across Caco-2 cells was conducted to examine the involvement of P-gp in transepithelial transport of fentanyl. Caco-2 cell lines were obtained from the American Type Culture Collection (Manassas, Virginia) and cultured as described previously (Oga et al., 2012) . Briefly, the cells were cultured at 37 C in 5% CO 2 at 90% humidity in DMEM high-glucose medium containing 15% fetal bovine serum, 1% nonessential amino acids, 100 U/ml penicillin and 1% streptomycin. For the efflux studies, the cells were seeded onto Millicell cell culture inserts (0.4 lm pore size, 6.5-mm diameter; Millipore Corporation, Billerica, Massachusetts) at a density of 3 Â 10 5 cells per well. The cells were then cultured for 20-22 days. Batches of Caco-2 cells were certified by measuring the transepithelial/transendothelial electrical resistance (TEER) values (Millicell ERS, Millipore Corporation) and the apparent permeability coefficient (P app ) of control compounds, atenolol (low permeability) and propranolol (high permeability). The acceptance criteria were as follows: TEER > 400 XÁcm 2 ; atenolol, P app(A-B) < 0.5 Â 10 À6 cm/s; propranolol, P app(A-B) between 15 Â 10 À6 and 25 Â 10 À6 cm/s. The expression of MDR1 on the Caco-2 cells was confirmed by quantitative PCR measurement using P-gp substrate digoxin as a positive control. Bi-directional transport assays were carried out from apical to basolateral side (A-B) (n ¼ 3) and basolateral to apical side (B-A) (n ¼ 3). Fentanyl (100 nM) was incubated with Caco-2 cells for 90 min with or without co-incubation with 1 mM of tariquidar, a known P-gp inhibitor (Zamek-Gliszczynski et al., 2012) . In another inhibition assay, KO-143, a BCRP inhibitor (5 mM) was used (Ebert et al., 2005) . The inhibitors were added into both apical and basolateral sides and coincubated with fentanyl at 37 C for 90 min. Apparent permeability was obtained according to the equation P app ¼ (dQ/d t )/(A Â C 0 ). The efflux ratio (ER) was calculated for each study using the following equation: ER ¼ P app(B-A) /P app(A-B) . ER value ! 2 indicates net efflux.
Protein binding of fentanyl in rat brain homogenate and plasma. The unbound fractions of fentanyl in rat brain homogenate and plasma were determined in a 96-well rapid equilibrium dialysis device (Thermo Fisher Scientific, Massachusetts), as previously reported in Chen et al. (2018) . Briefly, fresh rat plasma and brain homogenate (1:4 of brain to water, w/w) containing 50 ng/ml of fentanyl were freshly prepared on the day of the experiment. The plate was sealed and incubated at 37 C for 6 h. At the end of incubation, a 50-ll matrix sample (rat plasma or brain homogenate) and a 50-ll buffer sample were taken. A 50-ll aliquot of control buffer was added to the brain homogenate or plasma samples, and either a 50-ll aliquot of control brain homogenate or control plasma was added to the buffer samples to yield identical sample composition between buffer and non-buffer samples, then 300 ll of acetonitrile containing internal standard was added. The samples were vortex-mixed, centrifuged, and the supernatant was analyzed. The plasma unbound fraction was calculated as the concentration ratio of the buffer and the plasma. The unbound fraction in brain tissues was obtained using the following equation (Kalvass and Maurer, 2002) :
where D represents the factor of dilution of brain tissue (ie, 0.25 for a 4-fold dilution), and f u,measured is the ratio of concentrations determined from the buffer and brain homogenate samples.
In Vivo Studies Animals. The studies of pharmacokinetics, brain distribution, and respiratory functions were conducted in Sprague-Dawley rats (180-200 g), which were supplied by the animal center of the Institute. All the procedures for the animal experiments were approved by the Animal Ethics Committee of the Institute. The animals were maintained under a 12-h light/dark cycle in a temperaturecontrolled environment. Food and water were available ad libitum.
Plasma and brain concentrations of fentanyl. Fentanyl dosing solution (40 mg/ml) was prepared in normal saline. Tariquidar solution was prepared in 0.9% saline containing 10% dimethyl sulfoxide (DMSO). The rats in the fentanyl alone group received a single intravenous (i.v.) dose of fentanyl with the vehicle. The rats in the concomitant group were given the same i.v. dose of fentanyl 15 min after i.v. injection of tariquidar (10 mg/kg) (This dose regimen was applied to all the concomitant groups in in vivo studies). For low-dose groups, 60 male rats were randomly divided into 2 groups (fentanyl and concomitant group).
The fentanyl group received a 40 mg/kg fentanyl by i.v. injection. The concomitant group dosed with 10 mg/kg of tariquidar and then 40 mg/kg of fentanyl. Blood samples were collected at 5, 15, 30, 45, 60, and 90 min after the fentanyl dose (using 5 terminal rats at each time point). The rat hearts were immediately perfused with saline to remove the remaining blood, and rat brain samples were subsequently collected and frozen. The plasma was harvested by centrifugation of the blood at 2500 Â g for 15 min and stored at À20 C until analysis. To compare the plasma and brain exposures between male and female rats, 10 female rats in 2 groups (n ¼ 5 in each group) were given an i.v. dose of 40 mg/kg fentanyl with or without tariquidar. Plasma and brain samples were taken at 15 min after dosing and then treated as above. Based on the results of low dose groups, plasma and brain concentrations for fentanyl high-dose groups were determined in a simplified experiment. Two groups of 10 male rats each received an i.v. dose of 80 mg/kg of fentanyl with or without pretreatment of tariquidar (10 mg/kg). Blood and brain samples were collected at 5 and 15 min only (n ¼ 5), and analyzed. During tissue distribution studies, all the rats were also observed to determine the clinical signs of fentanyl-induced central opiate effects.
Fentanyl-induced loss of righting reflex. Thirty male rats were randomly divided into 6 groups with 5 rats in each group. The vehicle control and tariquidar groups received intravenously a vehicle media (0.9% saline containing 10% DMSO) or 10 mg/kg of tariquidar. The 2 fentanyl dose groups were intravenously administered with 40 mg/kg (low) or 80 mg/kg (high) of fentanyl, respectively. Two concomitant groups were the low-dose fentanyl and tariquidar group and the high-dose fentanyl and tariquidar group. Rats in these 2 groups were intravenously dosed with 40 mg/kg or 80 mg/kg of fentanyl 15 min after a tariquidar injection (10 mg/kg). In addition, 10 female rats in 2 groups were dosed with 40 mg/kg fentanyl with or without tariquidar. After treatment, all the rats were closely observed for signs of loss of righting reflex (LORR). The duration of LORR was measured and recorded individually for each rat. The onset of LORR was assessed by the inability of the rats to position themselves up right 3 times in 1 min after placement in the supine position in a V-shaped support until recovery.
Assessment of respiratory function. Fentanyl-induced respiratory depression and the effect of P-gp inhibition were quantitatively determined in awake, freely moving rats using a whole-body plethsmograph device (EMKA Technologies, Paris, France , and expiration time [ET]) was measured simultaneously to evaluate the respiratory functions of the rats. Since no differences were noted between male and female rats in brain exposure and fentanyl-induced LORR, this respiratory test was conducted using male rats only. In total 48 male rats were randomly divided into 6 groups, ie, vehicle control group, tariquidar group, low-and high-dose fentanyl groups, low-and high-dose fentanyl plus tariquidar groups. The dosing regimen and procedure were the same as the LORR studies. In the experiment, the conscious rats were firstly placed individually in the plethysmograph chamber for 30 min until a stable baseline was generated and recorded. After receiving different treatments as mentioned earlier, the rats were placed into the chambers again for an additional 75 min to record the alterations in respiratory parameters. All the data were analyzed using IOX software (EMKA Technologies). The results were plotted as mean % change of the respiratory parameter response to treatments relative to their corresponding baseline values versus time curves.
Quantitative Analysis of Fentanyl in Rat Plasma and Brain Samples
The quantification of fentanyl in plasma, brain homogenate and in vitro samples was conducted using an Aglient 6410 triple quadrupole mass spectrometer (Agilent Technologies, Santa Clara, California) equipped with an Agilent 1290 Infinity UHPLC system. The samples were separated on a CAPCELL PAK MG II C18 analytical column (100 Â 2.1 mm, 3 lm particle size, SHISEIDO, Japan), and eluted with aqueous solution contains 0.1 formic acid (v/v) and 5 mM ammonium formate (A) and acetonitrile contains 0.1% formic acid (v/v) (B). The gradient program applied was as follows: 0-0.7 min 30% B, 0.7-1.3 min 30%-80% B, 1.3-2.8 min 80%-30% B, followed by re-equilibration of 1.2 min. The flow rate was 0.35 ml/min. For quantification, the instrument was operated in the electron spray ionization (ESI) positive ion multiple reaction monitoring mode with the following optimized MS/MS conditions: transfer capillary temperature at 350 C; spray voltage of 4000 V, sheath gas of 30 psi.
The selected transitions were m/z 337.3!188.1 for fentanyl and m/z 260.1!116.2 for propranolol (IS). The determination method was validated following the U.S. Food and Drug Administration guidance (FDA-CDER, 2001 ). The linear quantitation ranges for fentanyl was from 0.5 to 100 ng/ml. The lower limit of detection was 0.5 ng/ml.
Data Analysis
Pharmacokinetic parameters from the concentration-time data in the plasma and brain were obtained by noncompartmental analysis performed using Phoenix WinNonlin 7.0 (Pharsight, California). The area under the concentration-time profiles for plasma (AUC plasma ) and brain (AUC brain ) were calculated using the linear trapezoidal method. The unbound brain-to-plasma partition coefficient (K p, uu, b/p ) of fentanyl (40 mg/kg) after i.v. administration with or without P-gp inhibitor was calculated as a ratio of AUC (AUC brain Âf u, brain /AUC plasma Âf u, plasma ), where f u, brain and f u, plasma are the fraction of unbound fentanyl in plasma and brain tissue, respectively.
RESULTS
ATP-Dependent Efflux of Fentanyl across P-gp and BCRP Expressed Membranes
ATPase screening assays with P-gp and BCRP expressed membranes were conducted to determine whether fentanyl was a substrate of these 2 primal efflux transporters on BBB. Digoxin and sulfasalazine were tested in parallel with fentanyl as positive controls. Results demonstrated that the orthovanadatesensitive ATPase activity of the P-gp membrane was significantly increased by digoxin and fentanyl (from 4.46 6 0.67 to 23.8 6 6.7 nmol/min/mg for digoxin and to 22.0 6 1.9 nmol/min/mg for fentanyl). For BCRP assay, the positive control, sulfasalazine, worked as expected where the ATPase activity increased from 10.5 6 1.2 to 49.3 6 2.1 nmol/min/mg. However, the measured ATPase activity in fentanyl incubation was found to be 11.6 6 0.2 nmol/min/mg only. The results suggested that fentanyl was a substrate of P-gp, but not for BCRP.
Effect of Transporter Inhibitors on Fentanyl Permeability across Caco-2 Cell
Bidirectional transmembrane transport across Caco-2 monolayer was performed with or without P-gp or BCRP inhibitor. The P app (A-B) of fentanyl obtained from the assays was in the range of 17.9 6 1.6 to 21.0 6 1.7 Â 10 À6 cm/s, indicating its high permeability across cell membrane. The net ER was found to be !2, which suggested that the efflux of the drug might involve the transporter-mediated active process. When co-incubated with tariquidar, a known P-gp inhibitor, the transport of the drug from apical to basolateral side (A-B) was significantly increased. The P app (A-B) of fentanyl increased to 1.9 fold of the individual control and the ER was reduced to 1.24 (Table 1) . However, the transepithelial efflux of fentanyl was not sensitive to inhibition by BCRP inhibitor KO-143 (Table 1 ). In the presence of KO-143, the P app (B-A) of fentanyl was notably reduced; however, the calculated ER was not significantly changed. Based on the results of ATPase and Caco-2 assays, fentanyl was recognized as a substrate of P-gp, but it was unlikely a BCRP substrate (FDA; CDER, 2012).
P-gp Inhibitor Elevated Brain Exposure of Fentanyl
The concentration-time curves of fentanyl in brain and plasma of male rats after i.v. dose alone (40 mg/kg) and in combination with tariquidar are shown in Figures 1A and 1B . To diminish the influence of nonspecific protein binding on fentanyl exposures between the plasma and brain, all the concentrations were corrected by measured f u, plasma (13.7% 6 2.1%) or f u, brain (8.6% 6 1.5%). The results showed that fentanyl could enter the brain rapidly, and maximum brain concentrations were observed at 5-min postinjection for both groups (Figure 1 ). This is in agreement with the lipophilic property of fentanyl as well as its high permeability across cell membranes. Moreover, the brain exposure of the free drug was higher than that in plasma, with the ratio of 1.6 (Figure 2 ). When coadministered with the inhibitor, the brain exposure (AUC) was significantly elevated from 109.3 6 29.3 ng/mlÁh of the fentanyl group to 295.1 6 44.6 ng/mlÁh of the combination group (Figure 2 ). However, it was interesting to note that the pharmacokinetics of fentanyl in plasma was not affected by pretreatment with tariquidar ( Figure 1B) . To assess the effect of sex on P-gp-mediated exposures of fentanyl, the plasma and brain concentrations between male and female rats were compared at 15 min after dosing. As illustrated in Figure 3 , no significant differences were observed between male and female rats in both fentanyl group and tariquidar concomitant group. In high fentanyl dose groups (80 mg/kg), the unbound fentanyl concentrations in brain and plasma at 5 min were 3.3-and 2.7-fold higher than the 40 mg/kg group, respectively. After the P-gp function was blocked by tariquidar, concentrations of unbound fentanyl were remarkably enhanced in brain, but not in plasma. The brain to plasma concentration ratios (K p, uu, b/p ) at 5 and 15 min were calculated to be 2.2-and 2.7-fold higher than the fentanyl alone group.
P-gp Inhibitor Prolonged the Duration of LORR Induced by Fentanyl
LORR is often used as an indicator of loss of consciousness or normal reflection to stimulation on the body/nerves. In this study, duration of LORR was determined to evaluate the sedative effect of fentanyl. Injection of vehicle or tariquidar did not cause LORR. Their inferences on fentanyl-induced LORR were therefore excluded. After i.v. injection of fentanyl to rats, the onset time of LORR was measured to be <20 s, and it was not affected by dosage increase and tariquidar pretreatment. However, the mean durations of LORR of male rats were increased from 16.3 6 4.9 min of 40 mg/kg group to 37.0 6 11.8 min of 80 mg/kg group, illustrating the dose-dependent CNS inhibition induced by fentanyl.
For the rats in fentanyl group and tariquidar concomitant group, durations of LORR were separately measured against their fentanyl alone groups. Tariquidar pretreatment significantly prolonged the duration of LORR (Figure 4) . The unconscious times of male rats in 40 mg/kg group and 80 mg/kg group Caco-2 cells were coincubated with 100 nM fentanyl and tariquidar (1 lM) or KO-143 (5 lM) at 37 C for 90 min (n ¼ 3).
*p < .001; **p < .01, compared with fentanyl group (n ¼ 3, mean 6 SD).
were measured to be 33.5 min (p < .01, 210%) and 61.0 min (p < .05, 160%), respectively. For female rats dosed with 40 mg/kg of fentanyl, the durations of LORR were measured to be 16.0 6 3.1 and 34.3 6 4.0 min for fentanyl alone group and tariquidar pretreatment group, respectively. Similar to the results of brain exposure, no significant sex difference was observed for fentanylinduced sedative effect. In all fentanyl-treated rats, symptoms of skeletal muscle rigidity were observed. When concomitant with tariquidar, the symptoms worsened, and the time was remarkably extended, in particularl among the high fentanyl dose groups.
P-gp Inhibitor Significantly Aggravated Fentanyl-Induced Respiratory Toxicity
Respiratory depression is known to be the life-threatening adverse effect of fentanyl. To assess the effect of P-gp inhibitor on the respiratory function of fentanyl treated rats, a panel of parameters was quantitatively measured. The respiratory patterns of rats treated with tariquidar and vehicle media were determined in parallel with fentanyl. As illustrated in Figure 5 , no significant differences in the respiratory parameters were observed between these 2 groups. Injection of tariquidar alone did not significantly alter the respiratory function of the rats. Following i.v. doses of 40 mg/kg fentanyl, remarkable respiratory depression was recorded during the period from 5 to 15 min ( Figure 6 ). In particular, 5 min after fentanyl injection, the respiratory rate (BPM) and minute ventilation (MV) sharply declined. At the same time, both duration of IT and ET increased significantly. Between 15 and 60 min, breathing of the rats gradually recovered to baseline level. The pattern of respiratory depression with increased timing and decreased drive was consistent with previous observations (Ferguson and Drummond, 2006; Smart et al., 2000) . When pretreated with tariquidar, significantly aggravated respiratory depression was recorded. Breathing parameters of the rats in the low-dose concomitant group showed 1.4-and 1.9-fold reduction in BPM and MV, as well as 2.8-and 3.9-fold increase in IT and ET when compared with the fentanyl only group. The maximum respiratory depression was also observed in the time frame from 5-to 15-min postdosing (Figure 6 ), corresponding to the higher level of brain exposure ( Figure 1A ). With the reduced fentanyl brain concentration at 15 min, the respiratory depression began to recover. At 60 min postdosing, the fentanyl concentration in brain declined to the level of quantitative limit, and all of the major respiratory indicators returned close to the baseline.
For high-dose fentanyl group (80 mg/kg), significantly impaired respiratory function was recorded. MV and BPM decreased in a dose-dependent manner, while IT and ET remarkably increased. Pretreatment with tariquidar further aggravated fentanyl-induced respiratory toxicity. MV and BPM decreased to approximately 60 and 80% of the baseline level, respectively; while IT and ET were 2.7-and 1.6-fold higher than the fentanyl alone group (Figure 6 ). At 60-min postdosing, the respiratory function of the rats in the high-dose concomitant group was not fully recovered. Moreover, 2 rats in this group died before completion of the experiment. Only 6 rats survived and were included in the final analyses. The mortality of the high-dose combination group was approximately 25%.
Relationships Between Brain Exposure and Fentanyl CNS Toxicity Based on the above results, associations between fentanyl brain exposure and sedative effect (duration of LORR) and respiratory toxicity were established for male rats in the 2 fentanyl groups and the 2 concomitant groups. As illustrated in Figure 7A , a plot of measured duration of LORR for the fentanyl groups with and without tariquidar against corresponding brain concentrations at 5 min showed a strong positive association (r 2 of 0.93).
Although aggravated respiratory depression (using MV as the representative indicator) was negatively associated with the elevated brain exposure following dose increasing and tariquidar treatment ( Figure 7B ). These observations indicated that rapid accumulation of fentanyl in CNS by P-gp inhibition resulted in severe and even lethal respiratory toxicity.
DISCUSSION
Fentanyl exerts its actions and toxicity by agonist binding at mopioid receptors in the CNS. Its high lipophilicity allows it to rapidly penetrate BBB to CNS (Roy and Flynn, 1988) . More recent studies have shown that fentanyl brain distribution involves complex mechanisms including both inward and outward transporter-mediated active transport (Elkiweri et al., 2009; Lö tsch et al., 2013) . However, observations on P-gp's role played in fentanyl penetration through BBB remained inconsistent (Hamabe et al., 2006; Park et al., 2007; Wandel et al., 2002) . Most of the previous studies on P-gp affinity status of fentanyl were either in vitro or in vivo only and hence needs to be interpreted with caution. This study is the one of the first to associate P-gp modulated BBB penetration with CNS toxicity of fentanyl by performing simultaneously both in vitro and in vivo evaluations. Several notable observations emerged. First, in vitro ATPase and Caco-2 assays indicated that fentanyl was a P-gp substrate. Second, pharmacokinetic study in rats demonstrated that brain exposure of fentanyl was significantly elevated by P-gp inhibitor tariquidar. Thirdly, in vivo toxicological study demonstrated a strong association between P-gp-modulated brain exposure and CNS toxicities. Taken together, these findings provide evidence that P-gp plays a vital role in modulating fentanyl brain exposure and its resulting CNS toxicity in rats. In this study, tariquidar, a selective third-generation P-gp inhibitor was used intravenously to inhibit P-gp on BBB. Tariquidar exhibits a high inhibitory potency for P-gp, with a 50% inhibitory concentration (IC 50 ) of 0.016 lM (Kannan et al., 2009) , and also has the advantage of minimal CYP-mediated interactions and toxicity (Bauer et al., 2010) . In addition to its inhibitory effects on intestinal or hepatic-biliary P-gp (Kong et al., 2016; Zhuang et al., 2013) , a number of animal studies have demonstrated that brain levels of several drugs were enhanced by tariquidar via inhibiting P-gp at the BBB. At a dosage of 10 mg/ kg, tariquidar almost blocked P-gp on rat BBB (Bankstahl et al., 2008; Gardner et al., 2009) , and at dosages >2 mg/kg, tariquidar could effectively block P-gp at human BBB (Bauer et al., 2013) . In agreement with previous studies, our data showed that tariquidar (i.v. 10 mg/kg) exerted an efficient inhibitory effect on the brain P-gp function in rats without significantly affecting respiratory functions ( Figure 5 ).
Fentanyl-related overdoses are characterized primarily by respiratory depression, accompanied by stupor and miosis (Boyer, 2012; Sporer, 1999) , where brain is the targeted site (Yong et al., 2014) . To characterize brain accumulation of fentanyl, the AUC ratio for unbounded drug between brain and plasma (K p, uu, b/p ) of male rats was calculated. The K p, uu, b/p of 1.6 suggested that the brain/plasma partition gradient of fentanyl was not reached by passive processes only, and the net transport of fentanyl through BBB was inwardly dominated and BPM (B), enhanced inspiratory time (C) and enhanced expiratory time (D) in response to fentanyl alone groups (n ¼ 8 for 40 and 80 mg/kg) and low-and high-dose fentanyl concomitant groups with tariquidar (n ¼ 8 for low-dose concomitant group; n ¼ 6 for high-dose concomitant group, the other 2 rats died of severe respiratory depression; mean 6 SD). *p < .05, **p < .01, the corresponding time point of tariquidar concomitant group vs. low-dose fentanyl group. # p < .05, ## p < .01, and ### p < .005, the corresponding time point of tariquidar concomitant group versus high-dose fentanyl group. (Di et al., 2013; Frid en et al., 2010) . Active uptake of fentanyl through BBB by uptake transporters might also contribute to its high brain exposure (Dagenais et al., 2004) . When the efflux function of P-gp was inhibited by tariquidar, the brain exposure of unbounded fentanyl was remarkably elevated (K p, uu, b/p of 4.6) to about 3-fold of the fentanyl alone group, highlighting the key role of P-gp in limiting fentanyl's entry into the CNS. Furthermore, sex is a biological variable that is known to contribute to interindividual variations in drug disposition, response, and toxicity (Morris et al., 2003) . Sex-related differences in membrane transportation of endogenous substrates and xenobiotics have been reported in various organs, such as kidney, liver and brain (Bebawy and Chetty, 2009; Morris et al., 2003) . In mdr1a deficient mice, modest influence of sex on BBB uptake of verapamil was observed, but not for the other 2 P-gp substrates, morphine and quinidine. It was suggested that the higher brain uptake of verapamil in female rat might reflect a flow-sensitive behavior (Dagenais et al., 2001 ). Similar to morphine, our study also did not observe notable sex differences in brain exposure and CNS effect of intravenously dosed fentanyl. In our study, respiratory function and duration of LORR were determined as 2 endpoints for fentanyl CNS toxicity. Respiratory depression induced by fentanyl is believed to result from m-opioid receptor-mediated inhibition of neuronal transmission in the rostro-dorsal surface of the pons, nucleus tractus solitarius, and nucleus ambiguus (Yong et al., 2014) . Our data showed that reduced respiratory functions by fentanyl displayed a pattern of fast on and fast off, which was consistent with the clinical observations of fentanyl intoxication (Fentanyl datasheet, Medsafe, New Zealand Medicines and Medical Devices Safety Authority, 2008). When high dose of fentanyl was cotreated with P-gp inhibitor, more severe respiratory suppression were observed in both degree and duration. Typical symptoms of stupor and flag tail were observed for all the rats in this group, and they lasted for >60 min. Muscular rigidity complication, in particular, wooden chest, has been recognized as the main cause of fentanyl-induced fatalities in illicit fentanyl abusers (Burns et al., 2016) . Besides the known CNS mechanism of fentanyl-induced respiratory depression, the prolonged muscular rigidity noted in our study was also a cause for aggravated breathing toxicity and death of the rats.
It was reported that, when concomitant with benzodiazepine and other CNS depressants (eg, anxiolytics, tranquilizers, muscle relaxants, and general anesthetics), fentanyl may result in harmful adverse effects such as sedation, respiratory depression, coma and death (Fentanyl datasheet, Medsafe, New Zealand Medicines and Medical Devices Safety Authority, 2008) . Coadministration with CYP3A inhibitors was also reported to influence metabolic elimination and pharmacological effects of fentanyl (Levin et al., 2010; Saari et al., 2008) . In addition to existing knowledge, our study found that inhibition of P-gp on BBB played a critical role in fentanyl-induced CNS toxicity. Because many market drugs are P-gp substrates or inhibitors (eg, cyclosporine A, ritonavir, verapamil, etc.), they could either compete with fentanyl for the same binding site on the protein or inhibit P-gp activity, and thus leading to drug-drug interaction related toxicity. This may be one of the causes for clinically observed fentanyl intoxication. When fentanyl is coadministered with Pgp inhibitors or substrates, a careful dosage adjustment may be necessary to reduce its CNS toxicity. Moreover, inter-individual variations in expression or activity of P-gp due to genetic polymorphisms should be considered to avoid complication of fentanyl treatment (Coulbault et al., 2006; Sadeque et al., 2000) . However, considering interspecies differences, extrapolation of the results from this rat study to humans warrant further studies.
In summary, this mechanistic study revealed the role of P-gp in the modulation of brain penetration of fentanyl and the association between its brain exposure and CNS toxicity. In vitro and in vivo evaluations provided convincing evidence that CNS accumulation of fentanyl and resulting respiratory depression are P-gp-dependent. The study indicated that the potential pharmacokinetic drug-drug interaction between fentanyl and P-gp substrates/inhibitors might lead to severe or even deadly consequences. A close monitoring is required in clinic when fentanyl is used in combination with P-gp inhibitors. assistance in respiratory function measurement, and Dr Chuang Lu from Sanofi Company, USA for his critical reading of the article.
